C
Constantinos Koumenis
Researcher at University of Pennsylvania
Publications - 156
Citations - 15751
Constantinos Koumenis is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Unfolded protein response & Tumor microenvironment. The author has an hindex of 52, co-authored 129 publications receiving 13837 citations. Previous affiliations of Constantinos Koumenis include Wake Forest University & Wake Forest Baptist Medical Center.
Papers
More filters
Journal ArticleDOI
19-nor-1α,25-Dihydroxyvitamin D2 (Paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo
Gary G. Schwartz,Dawn Eads,Christine Naczki,Scott A. Northrup,Tai C. Chen,Constantinos Koumenis,Constantinos Koumenis +6 more
TL;DR: Both 1,25(OH)2D3 and paricalcitol inhibited the growth of BxPC-3, Hs700T and AsPC-1 pancreatic tumor cell xenografts in nude mice at a dose that did not cause hypercalcaemia, accompanied by in vivo upregulation of p21 and p27 expression.
Journal ArticleDOI
Er translocation of the mapk pathway drives therapy resistance in BRAF-mutant melanoma
Rani Ojha,Nektaria Maria Leli,Angelique Onorati,Shengfu Piao,Ioannis I. Verginadis,Feven Tameire,Vito W. Rebecca,Cynthia I. Chude,Sengottuvelan Murugan,Colin Fennelly,Estela Noguera-Ortega,Charleen T. Chu,Shujing Liu,Xiaowei Xu,Clemens Krepler,Min Xiao,Wei Xu,Zhi Wei,Dennie T. Frederick,Genevieve M. Boland,Tara C. Mitchell,Giorgos C. Karakousis,Lynn M. Schuchter,Keith T. Flaherty,Gao Zhang,Meenhard Herlyn,Constantinos Koumenis,Ravi K. Amaravadi +27 more
TL;DR: BRAFi + MEKi-induced ER translocation of the MAPK pathway is necessary for ERK reactivation, which drives autophagy, which reconciles two major targeted therapy resistance pathways and identifies druggable targets, whose inhibition would likely enhance the response to BRAFi + MeKi.
Journal ArticleDOI
Modulation of CCAAT/Enhancer Binding Protein Homologous Protein (CHOP)-dependent DR5 Expression by Nelfinavir Sensitizes Glioblastoma Multiforme Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)
Xiaobing Tian,Jiangbin Ye,Michelle Alonso-Basanta,Stephen M. Hahn,Constantinos Koumenis,Jay F. Dorsey +5 more
TL;DR: Evidence is provided that Nelfinavir-induced ER stress modulates DR5 expression in human glioblastoma multiforme cells and can enhance TRAIL efficacy, providing a potential mechanistic rationale for the use of the Food and Drug Administration-approved agent NELFinavir in combination with DR5 agonists to induce apoptosis in human malignancies.
Journal ArticleDOI
1α,25-Dihydroxyvitamin D3 (calcitriol) and its analogue, 19-nor-1α,25(OH)2D2, potentiate the effects of ionising radiation on human prostate cancer cells
TL;DR: The synergistic effect at radiobiologically relevant doses of radiation suggests that a combination of 1 α,25-dihydroxyvitamin D3 or 19-nor-1α,25-(OH)2D2 with IR could permit a reduction in the dose of radiation given clinically and thus potentially reduce treatment-related morbidity.
Journal ArticleDOI
Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism
Supriya Shah,Whitney J. Carriveau,Jinyang Li,Sydney L. Campbell,Piotr K. Kopinski,Hee-Woong Lim,Natalie A. Daurio,Sophie Trefely,Kyoung-Jae Won,Douglas C. Wallace,Constantinos Koumenis,Anthony A. Mancuso,Kathryn E. Wellen +12 more
TL;DR: Evidence that metabolic features of prostate cancer cells can be exploited to sensitize CRPC cells to AR antagonism is provided, suggesting novel therapeutic opportunities for prostate cancer.